spacer
home > ebr > summer 2004 > apoptosis and chemotherapy: helping cancer cells to die
PUBLICATIONS
European Biopharmaceutical Review

Apoptosis and Chemotherapy: Helping Cancer Cells to Die

For an organism to develop multicellular tissues and organs, and to maintain cellular homeostasis during adulthood, the formation of new cells needs to be co-ordinated with the elimination of redundant and damaged cells. Apoptosis is the morphological manifestation of programmed cell death; the predominant mechanism that opposes and compliments cell proliferation. An imbalance between cell birth and death has pathological consequences: many chronic and acute degenerative disorders, as well as immunodeficiency diseases and infertility, are characterised by abnormally high rates of cell death in certain tissues. Conversely, suppression or retardation of apoptosis are distinguishing features in autoimmunity and cancer. Here I shall confine my discussion to the impact our current understanding of apoptotic signalling, as well as the mechanics of apoptosis, have on oncology drug discovery and development. Selective activation of programmed cell death in cancer cells is particularly desirable because apoptosis, as opposed to necrosis and other catastrophic cell injuries, leads to complete destruction and eradication of the aberrant cells without inflammatory and immunological side-effects.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Peter M Fischer, Head of Discovery Research at Cyclacel Limited

Peter M Fischer received his PhD from Deakin University, Australia. He has worked in academia, as well as the biotechnology and pharmaceutical industries on peptidomimetic and traditional medicinal chemistry projects related to drug discovery. For the last six years, he has been with the cancer research company Cyclacel, Scotland, for whom he established structure-based design and medicinal chemistry capabilities. He is currently Head of Discovery Research and focuses on cell cycle-related drug discovery targets, including CDKs and other protein kinases.

spacer
Peter M Fischer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Amcor partners with Moda to offer innovative packaging solutions

Amcor is pleased to announce its partnership with Moda vacuum packaging systems in North America and Latin America. By combining Amcor’s shrink bag and rollstock film for meat and cheese with Moda’s system, producers can gain operational efficiencies and drive total cost savings.
More info >>

White Papers

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Pharm-Olam, LLC

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin America—with their ready population of treatment naïve patients—can be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as “emerged” countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement